Sponsors Can Tap Real-world Data for ‘Intriguing’ New Ideas

Manufacturers of drugs, biologics and medical devices should be harnessing real-world data (RWD) at the postmarket stage, not just to support regulatory compliance but to generate ideas for innovative new products or indications, according to a former FDA official.
Source: Drug Industry Daily